Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Neboglamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 3/20 | 0.53 |
| ▸ | GRIN2B known ✓ | Q13224 | 3/20 | 0.53 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.41 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neboglamine SCHEMBL5083704 | 1.00 | LMNA (1.00) | LMNABLMGRIN1GRIN2BEPHX2 | |
| SCHEMBL3926158 | 0.73 | LMNA (0.57) | LMNABLMEPHX2CCKBR | |
| SCHEMBL3926164 | 0.73 | LMNA (0.57) | LMNABLMEPHX2CCKBR | |
| SCHEMBL10132091 | 0.73 | LMNA (0.56) | LMNABLMEPHX2DPP4DPP8 | |
| SCHEMBL30799584 | 0.73 | BLM (0.56) | LMNABLMGRIN1GRIN2BEPHX2 | |
| SCHEMBL3964164 | 0.72 | LMNA (0.55) | LMNABLMEPHX2 | |
| Hydrochloric Acid SCHEMBL29904534 | 0.71 | LMNA (0.54) | LMNABLMEPHX2 | |
| SCHEMBL14285665 | 0.70 | LMNA (0.54) | LMNABLMGRIN1GRIN2BDPP4 | |
| SCHEMBL14285569 | 0.70 | LMNA (0.54) | LMNABLMGRIN1GRIN2BDPP4 | |
| SCHEMBL3345888 | 0.69 | EPHX2 (0.53) | LMNABLMGRIN1GRIN2BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025065271-A1 | METHODS AND DEVICES FOR TREATING DEPRESSION | Liangzhu Laboratory (CN) | 2025-04-03 | — | — | WO | claimed |
| EP-3801527-B1 | FUSED GAMMA-CARBOLINES FOR ACUTE TREATMENT OF ANXIETY OR DEPRESSION | INTRA CELLULAR THERAPIES INC (US) | 2025-02-19 | — | — | EP | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| US-8258185-B2 | Use of neboglamine in the treatment of toxicodependency | ROTTAPHARM S.P.A. (IT) | 2012-09-04 | — | — | US | claimed |
| US-20110288173-A1 | Use of neboglamine in the treatment of toxicodependency | ROTTAPHARM S.P.A. (IT) | 2011-11-24 | — | — | US | claimed |
| US-20100197962-A1 | Use of Neboglamine in the Treatment of Toxicodependency | ROTTAPHARM S.P.A. (IT) | 2010-08-05 | — | — | US | claimed |
| EP-1940376-B1 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM SPA (IT) | 2009-03-18 | — | — | EP | claimed |
| EP-1940376-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2008-07-09 | — | — | EP | claimed |
| WO-2007039869-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2007-04-12 | — | — | WO | claimed |
| EP-1755583-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2007-02-28 | — | — | EP | claimed |
| WO-2005115373-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2005-12-08 | — | — | WO | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| EP-4665344-A1 | LUMATEPERONE AND DERIVATIVES THEREOF FOR MODULATING THE NERVOUS SYSTEM | Intra-Cellular Therapies, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12496300-B2 | Methods of treating acute depression and anxiety | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12485115-B2 | Biased NMDA receptor modulators and uses thereof | EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2007039869-A2 | USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY | ROTTAPHARM S.P.A. (IT) | 2007-04-12 | — | — | WO | disclosed |
| EP-1755583-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2007-02-28 | — | — | EP | disclosed |
| EP-1755583-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115373-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115373-A1 | USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE | ROTTAPHARM S.P.A. (IT) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | GRIN1 157/4885GRIN2B 379/4885GRIN2D 244/4885 |
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | GRIN1 71/4885GRIN2B 26/4885GRIN2D 38/4885 |
| US-12496300-B2 | Methods of treating acute depression and anxiety | HTR2A, HTR1A, HTR3B | GRIN1 323/4885GRIN2B 80/4885GRIN2D 110/4885 |
| US-12485115-B2 | Biased NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2B 7/4885GRIN2D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.